Abrocitinib, sold under the brand name Cibinqo, is a Janus kinase inhibitor medication used for the treatment of atopic dermatitis.
Routes of administration-oral.
Elimination half-life 2.8–5.2 h
Excretion 1.0–4.4% unchanged in urine
It is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.
The most common adverse effects in studies were upper respiratory tract infection, headache, nausea, and diarrhea.
It is a selective inhibitor of the enzyme janus kinase 1 (JAK1).
Pharmacokinetics: quickly absorbed from the gut and generally reaches highest blood plasma concentrations within one hour.
Only 1.0 to 4.4% of the dose are found unmetabolized in the urine.